HOME
ABOUT MORSE
The Team
Strategic Partners
Lorraine Boyle
Dominika Dabrowski
Stephen Filbey
Brent Korte
Careers
SERVICES
Our Services
Strategic Advice
MORSE HTA Strategic Advice
Analyses
Advisory Boards
MORSE Advisory Panel (MAP)
Training
Private Payer
Negotiation Simulation
Reimbursement Training
Reports
Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
Oncology and Biosimilar Sub-Report
NEWS
MORSE Signals
MORSE Wire
Publications
What’s New
EVENTS
LINKS
CONTACT US
HOME
ABOUT MORSE
The Team
Strategic Partners
Lorraine Boyle
Dominika Dabrowski
Stephen Filbey
Brent Korte
Careers
SERVICES
Our Services
Strategic Advice
MORSE HTA Strategic Advice
Analyses
Advisory Boards
MORSE Advisory Panel (MAP)
Training
Private Payer
Negotiation Simulation
Reimbursement Training
Reports
Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
Oncology and Biosimilar Sub-Report
NEWS
MORSE Signals
MORSE Wire
Publications
What’s New
EVENTS
LINKS
CONTACT US
pCPA
All the posts published.
CADTH Pharmaceutical Reviews Update – July 2019
August 16, 2019
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
pCPA Closing More Negotiations Without Agreements
August 6, 2019
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
Number of Active Negotiations (49) at Highest Level Since November 2018
July 7, 2019
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
The pCPA Initiates Negotiations for a Second “Group” of Oncology Biosimilars
June 18, 2019
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
April 2019 pCPA Update: The pCPA has completed over 250 negotiations
May 14, 2019
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
March 2019 pCPA Update: Two negotiations initiated prior to completion of CADTH process
April 8, 2019
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
pCPA Trends and Insights – Two Biosimilars Initiated Negotiations and Two Multi-Indication Negotiations were Completed
March 15, 2019
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
MORSE Consulting Releases its 2018 pCPA Year in Review Infographic
March 7, 2019
-
Market Access News
,
Publications
-
Posted by
MORSE Team
Read More →
Read More →
pCPA Negotiation Status Update January 2019 – Two Oncology Negotiations Closed without LOI
February 14, 2019
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
Spotlight on the Atlantic Provinces: pCPA Letter of Intent Conversion and Time-to-Listing Analysis
January 24, 2019
-
Market Access News
,
Publications
-
Posted by
MORSE Team
Read More →
Read More →
pCPA Process Timelines Highlights – A Year-in-Review Primer
January 15, 2019
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
pCPA Complete its Most Active Month by Adjudicating 15 Files in November
December 20, 2018
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
BC Pharmacare Now Transitioning Patients on Copaxone® to GLATECT™
November 29, 2018
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
Number of Active pCPA Negotiations at an All-Time High and Continues to Climb
November 19, 2018
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
Significant Developments in Canadian Drugs for Rare Disease Policy
November 14, 2018
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
Older posts
Newer posts
pCPA - Info and details on - Page 4 of 7 - MORSE Consulting Inc.
Private
Public
Private
INESSS
CADTH
HTA
pCPA
Public Payers
Health Canada
Patients
Private Payers
PMPRB
Public
INESSS
CADTH
HTA
pCPA
Public Payers
Health Canada
Patients
Private Payers
PMPRB
Public
Private
Public
INESSS
CADTH
HTA
pCPA
Public Payers
Health Canada
Patients
Private Payers
PMPRB
Private
INESSS
CADTH
HTA
pCPA
Public Payers
Health Canada
Patients
Private Payers
PMPRB